Skip to main content
Publications
Paller AS, Yosipovitch G, Weidinger S, DiBenedetti D, Whalley D, Gadkari A, Guillemin I, Zhang H, Eckert L, Chao J, Bansal A, Chuang CC, Delevry D. Development, psychometric validation and responder definition of worst itch scale in children with severe atopic dermatitis. Dermatol Ther. 2022 Dec;12(12):2839-50. doi: 10.1007/s13555-022-00804-z
Simpson EL, de Bruin-Weller M, Eckert L, Whalley D, Guillemin I, Reaney M, Chen Z, Nelson L, Qin S, Bansal A, Gadkari A. Responder threshold for Patient-Oriented Eczema Measure (POEM) and Children's Dermatology Life Quality Index (CDLQI) in adolescents with atopic dermatitis. Dermatol Ther. 2019 Dec;9(4):799-805. doi: 10.1007/s13555-019-00333-2
Huisman MV, Rothman KJ, Paquette M, Teutsch C, Diener HC, Dubner SJ, Halperin JL, Marin C, Ma CS, Zint K, Elsaesser A, Baretls DB, Lip GY. Antithrombotic treatment patterns in 10,871 patients with newly diagnosed non-valvular atrial fibrillation: the GLORIA-AF Registry Program, Phase II. Am J Med. 2015 Dec;128(12):1303-1313. doi: 10.1016/j.amjmed.2015.07.013
Garratt C, Weatherall M, Pohjanjousi P, Aantao R, Conti G, Lewis M, Moore N, Perez-Gutthann S. A multinational, drug utilisation study to investigate the use of dexmedetomidine (DEXDOR®) in clinical practice in the EU. Poster presented at the 2015 ESICM's 28th Annual Congress; October 3, 2015. Berlin, Germany. [abstract] Intensive Care Med Exp. 2015 Oct 1; 3(Suppl 1):A322. Previously presented at the 31st ICPE International Conference on Pharmacoepidemiology and Therapeutic Risk Management. doi: 10.1186/2197-425X-3-S1-A322